Sharaf Ala'a, Hashim Hashim
Female and Functional Urology Unit, Bristol Urological Institute, Bristol, UK.
Drug Des Devel Ther. 2017 Feb 20;11:463-467. doi: 10.2147/DDDT.S101630. eCollection 2017.
Mirabegron is a relatively new drug introduced to treat overactive bladder syndrome. It can be used either on its own or as part of a combination. This drug has been extensively studied, with a good number of Phase II and Phase III trials showing promising outcomes. These studies show that mirabegron is an effective, well-tolerated drug, which could have some adverse effects of concern. In this review, we look at the trials on mirabegron, as well as its pharmacokinetics, mechanism of action, and side effects as documented in the literature.
米拉贝隆是一种用于治疗膀胱过度活动症综合征的相对新药。它既可以单独使用,也可以作为联合用药的一部分。这种药物已经得到广泛研究,大量的II期和III期试验显示出有前景的结果。这些研究表明,米拉贝隆是一种有效且耐受性良好的药物,但可能存在一些值得关注的不良反应。在本综述中,我们将探讨关于米拉贝隆的试验,以及其在文献中记载的药代动力学、作用机制和副作用。